Home » Topics » Regulatory » EMA

EMA
RSS

European CHMP recommends marketing authorization for Tigenix's ChondroCelect

July 2, 2009

CHMP adopts positive opinion for Otsuka's Samsca in hyponatremia

June 12, 2009

CHMP recommends granting of marketing authorization for Orphan Europe's Vedrop

June 11, 2009

EMEA provides information on possible interaction between clopidogrel and PPIs

June 9, 2009

Sepracor withdraws marketing authorization application for Lunivia (eszopiclone)

May 19, 2009

The European Commission withdraws marketing authorization for Velosulin

April 20, 2009

CHMP recommends marketing authorization for Astellas' Modigraf in transplant rejection

March 24, 2009

CHMP recommends marketing authorization for HRA's emergency contraceptive ellaOne

March 24, 2009

Bristol-Myers Squibb withdraws marketing authorization application for Ixempra

March 23, 2009

EMEA recommends continued vaccination with Gardasil

Feb. 23, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...